COMMUNIQUÉS West-GlobeNewswire

MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors

12/11/2018 - 10:11

SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. Magda [...]

AC Immune to Present at the Jefferies 2018 London Healthcare Conference

12/11/2018 - 10:01

Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will [...]

Rule 2.9 Announcement

12/11/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 November 2018 [...]

Appointment of Joint Broker

12/11/2018 - 08:00

Summit Therapeutics plc (‘Summit’ or the ’Company’) Appointment of Joint Broker Oxford, UK, and Cambridge, MA, US, 12 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism [...]

Publication of Scheme Document

12/11/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]

Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC

12/11/2018 - 07:02

SITC 2018: FURTHER ANALYSES OF THE PHASE II STUDY OF THE COMBINATION OF MONALIZUMAB AND CETUXIMAB IN HEAD AND NECK PATIENTS SHOW ENCOURAGING SURVIVAL DATA IN BOTH SUBGROUPS OF IO-NAÏVE AND IO-PRETREATED SCCHN PATIENTS [...]

Innate Pharma a présenté des données translationnelles de la Phase II de monalizumab avec cetuximab au SITC

12/11/2018 - 07:02

SITC 2018 : DES ANALYSES COMPLEMENTAIRES DE LA PHASE II DE LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB DANS LES CANCERS DE LA TÊTE ET DU COU MONTRENT DES DONNÉES DE SURVIE ENCOURAGEANTES DANS LES DEUX SOUS-GROUPES DE [...]

Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference

12/11/2018 - 07:00

Geneva, Switzerland, 12 th November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will provide a [...]

Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval

12/11/2018 - 01:59

NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2 trial in end-stage heart [...]

BioPorto A/S increases the share capital through a cash issue, private placement.

11/11/2018 - 22:55

November 11, 2018 Announcement no. 19 BioPorto A/S increases the share capital through a cash issue, private placement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES [...]

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

11/11/2018 - 17:46

Entresto ® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker for heart failure [...]

Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause

11/11/2018 - 14:17

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent ® (alirocumab) was associated with fewer deaths from any cause Mortality risk reduction greater in patients treated for at least 3 years or those with [...]

Sanofi : Au Congrès de l'AHA, les investigateurs d'ODYSSEY OUTCOMES présentent des données montrant que Praluent® (alirocumab) a été associé à un nombre réduit de décès toutes causes confondues

11/11/2018 - 14:17

Au Congrès de l'AHA, les investigateurs d'ODYSSEY OUTCOMES présentent des données montrant que Praluent ® (alirocumab) a été associé à un nombre réduit de décès toutes causes confondues Une réduction du risque de [...]

Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

10/11/2018 - 23:00

CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab Novel adenosine gene signature biomarker associated with response to [...]

AI Algorithm Outperformed Majority of Cardiologists in Detection of Heart Murmurs in Clinical Study

10/11/2018 - 20:15

Eko’s heart murmur detection algorithm outperformed four out of five cardiologists for the detection of heart murmurs in a recent clinical study. The algorithm is designed to empower four million U.S. clinicians to [...]

ACC, AHA Release 2018 Guideline on the Management of Blood Cholesterol at AHA Scientific Sessions

10/11/2018 - 18:55

NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The American College of Cardiology and American Heart [...]

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

10/11/2018 - 18:20

- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: [...]

Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy

10/11/2018 - 16:00

AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised [...]

Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

10/11/2018 - 14:01

Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company [...]